bioAffinity Q3 2025: revenue down to $1.5M, CyPath Lung revenue up 122% YoY, net loss $5.1M

bioAffinity Technologies, Inc.

2025-Q3 EPS reported -$7.55 revenue$4,569,146

Total revenue $1.5M in Q3 2025, down 38% from $2.4M in Q3 2024 due to discontinuation of unprofitable pathology services.
CyPath Lung testing revenue increased 122% YoY; test volumes up 97% in first nine months of 2025.
Net loss $5.1M ($4.74 per share) compared to $2.0M loss ($4.84 per share) in Q3 2024, driven by change in fair value of warrants.
Raised $10.4M gross proceeds from equity transactions; cash and equivalents increased to $7.7M from $1.1M at year-end 2024.
Appointed Roberto Rios and John J. Oppenheimer to board; regained full Nasdaq compliance for listing of BIAF and BIAFW.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.